RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. grew its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 3.9% during the third quarter, HoldingsChannel reports. The firm owned 2,023,305 shares of the company’s stock after buying an additional 76,356 shares during the period. Vanguard Group Inc. owned 0.06% of RAPT Therapeutics worth $33,627,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in RAPT. State Street Corp grew its holdings in RAPT Therapeutics by 159.5% during the 3rd quarter. State Street Corp now owns 1,273,891 shares of the company’s stock valued at $30,650,000 after purchasing an additional 783,026 shares in the last quarter. Perceptive Advisors LLC grew its stake in shares of RAPT Therapeutics by 27.4% during the first quarter. Perceptive Advisors LLC now owns 2,291,608 shares of the company’s stock valued at $42,051,000 after acquiring an additional 492,653 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of RAPT Therapeutics by 9.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,334,683 shares of the company’s stock worth $79,108,000 after acquiring an additional 359,978 shares during the last quarter. Woodline Partners LP acquired a new position in shares of RAPT Therapeutics in the first quarter worth about $7,882,000. Finally, Polar Asset Management Partners Inc. purchased a new position in RAPT Therapeutics in the first quarter valued at about $5,797,000. 99.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages recently issued reports on RAPT. JPMorgan Chase & Co. dropped their price target on shares of RAPT Therapeutics from $15.00 to $13.00 and set a “neutral” rating for the company in a research note on Wednesday, March 27th. Cantor Fitzgerald lowered shares of RAPT Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Tuesday, February 20th. SVB Leerink cut shares of RAPT Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the stock from $42.00 to $10.00 in a research report on Wednesday, February 21st. UBS Group lowered RAPT Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $61.00 to $10.00 in a report on Thursday, February 22nd. Finally, Wolfe Research initiated coverage on RAPT Therapeutics in a research note on Thursday, February 15th. They set an “outperform” rating and a $39.00 price objective on the stock. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.67.

RAPT Therapeutics Price Performance

Shares of NASDAQ RAPT opened at $9.38 on Friday. The firm has a market capitalization of $326.42 million, a PE ratio of -3.09 and a beta of 0.47. RAPT Therapeutics, Inc. has a 1-year low of $6.86 and a 1-year high of $27.35. The business’s fifty day moving average price is $12.72 and its two-hundred day moving average price is $16.08.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.05. Equities research analysts expect that RAPT Therapeutics, Inc. will post -3.19 earnings per share for the current fiscal year.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.